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The aim of this study is to explore the mechanisms by which electroacupuncture (EA) enhances the hypoglycemic eﬀect of
exogenous insulin in a streptozotocin- (STZ-) diabetic rats. Animals in the EA group were anesthetized and subjected to the
insulin challenge test (ICT) and EA for 60 minutes. In the control group, rats were subjected to the same treatment with the
exception of EA stimulation. Blood samples were drawn to measure changes in plasma glucose, free fatty acids (FFA), and insulin
levels. Western blot was used to assay proteins involved in insulin signaling. Furthermore, atropine, hemicholinium-3 (HC-3), and
Eserine were used to explore the relationship between EA and cholinergic nerve activation during ICT. EA augmented the blood
glucose-lowering eﬀects of EA by activating the cholinergic nerves in STZ rats that had been exposed to exogenous insulin. This
phenomenon may be related to enhancement of insulin signaling rather than to changes in FFA concentration.
1.Introduction
Insulin therapy has revolutionized the treatment of diabetes
mellitus (DM) and has contributed to increased longevity
and improved quality of life for people with diabetes [1].
Insulin resistance, however, can develop up to a decade
before the onset of diabetes, and insulin insensitivity
increases the risk of macroangiopathy [2]. According to
Zimmet et al., the worldwide prevalence of diabetes will
increaseby50%by2010,withthehighestincreasesoccurring
in Asian countries [3]. In order to prevent the formation
of insulin resistance, agents and/or methods for enhancing
insulin sensitivity become important topic recently.
Previous research on the use of electroacupuncture (EA)
to reduce blood glucose levels showed that using speciﬁc
frequencies to stimulate points on the middle part of the
abdomen (Zhongwan acupoint) of rats could signiﬁcantly
reduce plasma glucose levels. The mechanism of action
involved the stimulation of the release of β-endorphins,
which subsequently increased insulin production in animal
models of type II DM. In addition, stimulation of Zhongwan
acupoints results in signiﬁcantly greater plasma glucose-
lowering eﬀects than stimulation of adjacent nonacupunc-
ture points [4]. Other studies showed that EA applied to the
Zusanli (ST-36) or Zhongwan acupoints enhanced insulin
sensitivity in rats although the mechanisms of action were
not investigated [5, 6].
In the selection of parameters and acupoints for EA to
lower plasma glucose, previous experiments performed on
normal Wistar rats compared the glucose-lowering eﬀects of
diﬀerent EA frequencies (2Hz, 15Hz, and 100Hz) applied
to Zhongwan acupoints. The most signiﬁcant reduction in2 Experimental Diabetes Research
plasma glucose levels was elicited by EA at a frequency
of 15Hz [4]. Chang et al. compared the plasma glucose-
loweringeﬀectsofEA(2Hz)appliedtoacupointsonthefoot
(Zusanli acupoint) and on the abdomen of rats (Zhongwan
acupoint).TheresultsshowedthatstimulationoftheZusanli
acupoint had better glucose-lowering eﬀects than stimula-
tion of the Zhongwan acupoint. The glucose-lowering eﬀects
of EA applied to the Zusanli acupoint involve the release
of serotonin in addition to endogenous opioid peptides [7].
The results from those studies imply that stimulation of the
Zusanli acupoint elicits a better hypoglycemic eﬀect than
stimulation of the Zhongwan acupoint.
Otherwise, Shapira et al. applied EA to the Zhongwan
acupoint of fat sand rats with insulin resistance and found
that EA produced a sustained noninsulin dependent reduc-
tion in glucose levels. They reported that their protocol
eﬀectively delayed disease onset in animals and increased
the survival rate [8]. Chang et al. used the insulin challenge
test (ICT) and intravenous glucose tolerance test (IVGTT)
to study whether 15Hz stimulation of Zusanli acupoints
increased insulin sensitivity [5]. They found that the eﬀect
was even more apparent in animals that had been injected
with steroids to induce insulin resistance and that the
sensitizing eﬀects were related to free fatty acids (FFAs) in
s t e r o i db a c k g r o u n dr a t s( S B R s )[ 9, 10]. FFAs cause insulin
resistance in all major insulin target organs (skeletal muscle,
liver, and endothelial cells) and have emerged as a major
link between obesity, the development of the metabolic
syndrome, and atherosclerotic vascular disease [11]. The
homeostaticmodelassessmentindex(HOMA)isaneasyway
toevaluateinsulinresistance[10,12];therefore,inthisstudy,
the FFAs and HOMA were used to explore the eﬀects of EA
on enhancing the hypoglycemic eﬀect of exogenous insulin.
A recent study showed that EA at the Zusanli acupoint
reduced plasma glucose levels by stimulating the cholinergic
nerves and by inducing the upregulation of the insulin sig-
naling proteins IRS-1 and AKT-2 [13]. Hsieh et al. tested the
eﬀects of low-frequency (2Hz) and high-frequency (100Hz)
EA stimulation at the ST-36 acupoint on heart rate and skin
temperature in humans and found that high-frequency EA
stimulation led to a reduction in heart rate by activating
parasympathetic nerves [14]. Thus, we hypothesized that
the cholinergic nerves are involved in enhancing exogenous
insulin sensitivity in a STZ-induced diabetic rat model. The
aimofthisstudywastoexplorethemechanismsbywhichEA
enhances the hypoglycemic eﬀect of exogenous insulin in a
streptozotocin- (STZ-) induced diabetic rat model. We used
antagonistsofcholinergicnerves,Atropine,Hemicholinium-
3 (HC-3), and Eserine, to explore the relationship between
cholinergic nerve stimulation and EA-induced exogenous
insulinsensitivity. Atropineisacompetitiveantagonistofthe
muscarinic acetylcholine receptor; HC-3 indirectly reduces
Ach by suppressing choline reuptake in the cholinergic
nerve ending, thereby reducing Ach concentrations between
synapses and suppressing the activity of cholinergic nerves
[13, 15, 16], and Eserine is an inhibitor of cholinesterase for
enhancing cholinergic tone [17]. They were used through
three diﬀerent ways for exploring the mechanisms relative to
cholinergic nerve in EA actions.
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Figure 1: Time schedule of the protocol for exploring the
relationship between the cholinergic nerve and the enhancing
hypoglycemic eﬀect of insulin by EA: STZ: streptozotocin-induced
diabetic rats, ICT begin: the beginning point of insulin challenge
test, Atropine/HC-3/Eserine: each agent was given at 30min before
ICTseparately, EA:theexperimentalgrouptreatedEA,non-EA:the
control group not treated EA.
2.MaterialsandMethods
2.1. Animal Model. Normal male Wistar rats weighing
approximately 250–350g and aged 8–10 weeks were pur-
chased from the BioLASCO animal center. Type 1 diabetes
was induced by administration of STZ (60mg/kg, i.v.) via
the femoral vein under a fasting state [13]. Animals were
housed in plexiglass cages at a constant room temperature
of 22 ± 2◦C with a relative humidity of 65 ± 5%. Rats
were fed standard rat chow and were given free access to
water. Animals were randomly divided into experimental
groups and control groups after an adaptation period of one
week, and all the animals in this study were anesthetized
using pentobarbital (40mg/kg i.p.). All animals were treated
in accordance with the National Institute of Health (NIH)
Guide for the Care and Use of Laboratory Animals, and the
study protocol was approved by the ethics committee of the
China Medical University, Taichung, Taiwan.
2.2. Electroacupuncture (EA). Acupoints were located
according to body length measurement as described
elsewhere [18]. The ST-36 acupoint was located on the
anterior tibia muscle approximately 5mm below the knee.
Bilateral ST-36 acupoints were punctured in a vertical and
deep manner with 1.27cm, 32 gauge acupuncture needles.
After a 5-min needling period, EA was performed for 30
minutes at a frequency of 15Hz and the amplitude of
10mA using a HANS LY257 acupoint and nerve stimulator
(Healthtronics, Singapore).
2.3. Plasma Glucose and FFA Assay. Approximately 0.3–
0.5mL of blood was obtained from a femoral vein under
anesthesia using a 1mL syringe containing heparin. The
collectedblood wasintroduced into eppendorﬀ tubes, lightly
shaken, and then stored on ice. Following centrifugation at
21380×g for 50 minutes, the plasma glucose (mg/dL) and
plasma FFA levels (meq/L) were determined using a spec-
trophotometer (COBASR system, Roche, Switzerland, USA).
2.4. Insulin Challenge Test and Plasma Insulin Assay. After
administration of regular insulin 1U/kg i.p. (Novo Nordisk
Company, Denmark) 30min after onset of hypoglycemia
[5], blood samples were taken from a femoral vein at
0, 30, and 60min and assayed for plasma glucose levels.Experimental Diabetes Research 3
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Figure 2: The plasma glucose-level-lowering eﬀe c to fE Aa p p l i e dt o
the bilateral Zusanli acupoints on STZ rats after ICT. EA represents
12 hours of fasting and application of EA; non-EA shows the same
except application of EA. Comparison of plasma glucose levels 30
and 60 minutes between EA and non-EA group under ICT, ∗∗P<
.01 by Student’s t-test.
Plasma insulin levels were measured using an ELISA kit
(EZRMI-13K, Linco Research, Inc., USA). In brief, samples
were incubated for 2h at room temperature in a shaker
and then exposed to peroxidase conjugate and antibodies
bound to a microtitration well. A conjugate was detected
by reaction with 3,3 ,5,5 -tetramethylbenzidine (TMB). The
reactionwasstoppedbyaddingacid.Themixturewasshaken
to produce a colorimetric endpoint that was read using a
spectrophotometer. The values obtained were noted as pmol
of peptide per liter of plasma.
2.5. Study Protocol
2.5.1. Plasma Glucose Reduction under Insulin Challenge.
STZ-induced diabetic rats (N = 19) were randomly divided
into an EA group (N = 8) or a control group (N = 11).
Animals in the EA group were anesthetized, subjected to the
ICT, and then stimulated by EA for 60 minutes. Rats in the
control group were anesthetized and subjected to ICT but
did not undergo EA. Blood was extracted for glucose, FFAs,
and insulin testing at the beginning of the experiment, 30
minutesoftheexperiment,and60minutesoftheexperiment
as previously described [5].
2.5.2.PharmacologicalExplorationofMechanisms. Thephar-
macological agents, Atropine 0.1mg/kg, HC-3 0.01mg/kg,
and Eserine 0.01mg/kg, were injected separately into the
abdomens of STZ-induced diabetic rats 30 minutes prior
to the experiment in order to block or enhance cholinergic
activity [13, 17]. A total of 48 rats were used to explore
the mechanism. After exposure to the three pharmacological
agents,rats(N = 16)werethenrandomlydividedintoanEA
group(N = 8)oracontrolgroup(N = 8).AnimalsintheEA
group were subjected to the ICT and then EA stimulation for
60 minutes. Rats in the control group were anesthetized and
subjected to ICT but did not receive EA. Blood was extracted
for glucose testing prior to the experiment and at 30 and
60 minutes into the experiment as previously described [5].
T h ep r o t o c o lo ft h i sp r o c e d u r ei ss u m m a r i z e di nF i g u r e1,
and the two groups (EA and non-EA) were compared in the
same background of cholinergic tone [19]. In the atropine
blocking experiment, the plasma insulin and FFAs were also
assayed.
2.5.3. Western Blotting Analysis. Fasting STZ rats (N = 12)
were randomly divided into EA and non-EA groups. The
other fasting STZ rats (N = 12) were randomly divided
into an EA and non-EA group 30min after treatment with
atropine 0.1mg/kg, i.p. At the end of EA treatment (30min)
in each group, portions of the gastrocnemius muscles were
taken as samples for analysis of insulin signaling proteins
(IRS-1,AKT-2).Musclesampleswerehomogenizedinbuﬀer
solution before centrifugation at 13980×g. The obtained
supernatant was used to estimate the amount of protein
using an assay kit from Bio-Rad Laboratories. The super-
natant (protein) was mixed with 4X SDS-loading dye and
boiled for 15min at 95◦C for denaturing. Separating (8%)
and stacking gels were prepared. Then, protein (90μg/mL)
in buﬀer was loaded into each well for electrophoresis. Pro-
teins were electrophoretically transferred to polyvinylidene
diﬂuoride (PVDF) membranes at 4◦C. The membranes were
thenblockedwith5%nonfatdrymilkinphosphate-buﬀered
saline(PBS)for1hratroomtemperatureandincubatedwith
the speciﬁc primary antibodies (Santa Cruz Biotechnology,
Inc.). After the membranes had been washed in a buﬀer con-
taining 0.1% Tween 20 in 1 × PBS, blots were incubated with
a horseradish peroxidase-linked speciﬁc secondary antibody
(SantaCruzBiotechnology,Inc.)andthenevaluatedusingan
enhanced chemiluminescence detection using ECL reagent
plus (PerkinElmer Life Sciences, Inc.). Band intensities were
quantiﬁed by densitometry to observe the target proteins.
2.6. Statistical Analysis. A l lv a l u e sa r ee x p r e s s e da sm e a n
± SE. The HOMA was used to evaluate insulin resistance.
HOMA = insulin (μU/mL) × glucose (mmol/L)/22.5 [10,
12].Theparameter,areaundercurve(AUC),iscalculatedfor
comparison by the statistical software, MedCalc. Diﬀerences
in mean values between the experimental group (EA) and
control group (non-EA) were tested by the Student’s t-test. A
self-paired t-test was used to determine signiﬁcant changes
in levels of plasma indicators before and after treatment. For
all comparisons, a P value <. 05 (two-sided) was considered
to represent statistical signiﬁcance.
3. Results
3.1. Eﬀects of EA on STZ Rats under ICT. STZ-induced
diabetic rats (N = 19) were ﬁrst subjected to ICT and then4 Experimental Diabetes Research
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Figure 3: (a) Blocking eﬀect of atropine on STZ rats received EA during ICT (b) Impact of HC-3 on the plasma glucose-lowering action in
STZ rats subjected to ICT. EA represents 12 hours of fasting and application of EA; non-EA shows the same without application of EA. The
plasma glucose levels were compared between EA and non-EA group at 30 and 60 minutes during ICT by Student’s t-test.
Table 1: EA (15Hz) was applied to the bilateral Zusanli acupoints on STZ rats under ICT.
Plasma levels Groups 0min 30min 60min
Insulin (ng/mL) EA 0.44 ± 0.30 3.66 ± 3.96 5.98 ± 2.42
non-EA 0.33 ± 0.31 6.93 ± 4.17 5.94 ± 3.70
HOMA EA 15.4 ± 11.2 77.9 ± 73.7∗ 65.6 ± 35.7∗
non-EA 10.2 ± 11.4 228.7 ± 92.5 152.4 ± 76.0
FFAs (mmol/L) EA 1.05 ± 0.38 0.48 ± 0.31 0.44 ± 0.24
non-EA 1.04 ± 0.33 0.47 ± 0.16 0.39 ± 0.19
All values are expressed as mean ± SE; HOMA = insulin (μU/mL) × glucose (mmol/L)/22.5. The value of EA group (N = 8) was compared with the value
of non-EA (N = 11) group by Student’s t-test, ∗P<. 05.
randomly and equally divided into an EA group or a non-
EA group. Rats in the EA group received EA at the Zusanli
acupoint for 60 minutes. Rats in the control group did not
receive EA. After 60 minutes, the mean blood glucose level in
the EA group was 224.0 ± 86.2 mg/dL and that in the control
group was 393.6 ± 160.2mg/dL. Also, the AUC of EA group
was 23202 ± 3411 and that in the non-EA group was 28737
± 6181. The diﬀerences of plasma glucose level after 60 min
and AUC between EA and non-EA were signiﬁcant (P<. 05)
(Figure 2).
3.2. Blockage Eﬀects of Atropine on STZ Rats Subjected to ICT.
After administering Atropine 0.1mg/kg i.p., 15Hz EA was
appliedtotheZusanliacupointinnormalratsfollowingICT.
The blood glucose levels were then compared with those
in the non-EA group. There were no signiﬁcant diﬀerences
in blood glucose levels between the two groups. After 60
minutes, the mean blood glucose level in the EA group was
394.5 ± 167.0 mg/dL and that in the control group was
373.6 ± 67.8 mg/dL. Also, the AUC of EA group was 26502
± 9264 and that in the non-EA group was 25896 ± 3795.
The diﬀerences of plasma glucose level after 60min and
AUC between EA and non-EA were not signiﬁcant (P>
.05), indicating that atropine eﬀectively blocked the glucose-
lowering eﬀects of EA in STZ-induced diabetic rats that had
been subjected to insulin challenge (Figure 3(a)).
3.3. Blockage Eﬀects of HC-3 on STZ Rats Subjected to ICT.
After administering HC-3 0.01mg/kg i.p., 15Hz EA was
applied to the Zusanli acupoint in STZ-induced diabetic rats
under ICT. The blood glucose values were compared with
those in the non-EA group. No signiﬁcant diﬀerences in
b l o o dg l u c o s el e v e l sw e r en o t e d .A f t e r6 0m i n u t e s ,t h em e a n
blood glucose level in the EA group was 385.5 ± 161.4mg/dL
and that in the non-EA group was 406.7 ± 149.7mg/dL.
Also, the AUC of EA group was 26911 ± 7742 and that in
the non-EA group was 27985 ± 7709. The diﬀerences of
plasma glucose level after 60min and AUC between EA andExperimental Diabetes Research 5
Table 2: Atropine blocking eﬀect in 15Hz EA on the bilateral Zusanli acupoints under ICT.
Plasma levels Groups 0min 30min 60min
Insulin (ng/mL) EA 0.10 ± 0.09 1.97 ± 3.04 1.85 ± 2.89
non-EA 0.04 ± 0.04 4.85 ± 6.97 4.10 ± 6.16
HOMA EA 2.6 ± 3.2 73.6 ± 87.8 55.2 ± 69.4
non-EA 1.2 ± 1.2 114.1 ± 162.0 81.6 ± 123.6
FFAs (mmol/L) EA 0.97 ± 0.21 0.57 ± 0.27 0.57 ± 0.28
non-EA 0.94 ± 0.42 0.62 ± 0.40 0.59 ± 0.46
A l lv a l u e sa r ee x p r e s s e da sm e a n± SE; HOMA = insulin (μU/mL) × glucose (mmol/L)/22.5. The value of EA group (N = 8) was compared with the value of
non-EA group (N = 8) by Student’s t-test.
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Figure 4: Eﬀect of Eserine on the plasma glucose reduction eﬀects
of EA applied to the Zusanli acupoint in STZ rats during ICT. EA
represents 12 hours of fasting and application of EA; non-EA shows
the same without application of EA. The plasma glucose levels were
compared between EA and non-EA group at 30 and 60 minutes
during ICT, ∗∗P<. 01 by Student’s t-test.
non-EA were not signiﬁcant (P>. 05), indicating that HC-
3e ﬀectively blocked the glucose-lowering eﬀects of EA in
STZ-induced diabetic rats that had been subjected to insulin
challenge (Figure 3(b)).
3.4. Eﬀects of Eserine on STZ Rats Subjected to ICT. After
administering Eserine 0.01mg/kg i.p., 15Hz EA was applied
to the Zusanli acupoint in STZ-induced diabetic rats after
ICT. The blood glucose values were compared with those
in the non-EA group. The results showed that 30 minutes
afterratshadbeeninjectedwithEserine(0.01mg/kgi.p.),EA
(15Hz) applied to the Zusanli acupoint for 60min led to a
62.1%reduction(from500.6 ±57.6to199.8 ±151.8mg/dL)
in plasma glucose. This represents a signiﬁcant increase over
the 26.6% (from 560.9 ± 69.9 to 415.6 ± 136.1mg/dL) blood
sugar reduction (non-EA) associated with EA plus Eserine
(N = 8, P<. 05) (Figure 4). Also, the AUC of EA group
was 21203 ± 6226 and that in the non-EA group was 30114
± 5906. The diﬀerences of plasma glucose level after 60min
and AUC between EA and non-EA were signiﬁcant (P<
.05), indicating that Eserine eﬀectively augmented the blood
glucose-lowering eﬀects of EA in STZ rats that had been
subjected to insulin challenge.
3.5. Changes in Insulin and FFA Concentrations and HOMA
Values under ICT. EA (15Hz) was applied to the Zusanli
acupoint in STZ rats under ICT. The insulin and FFA
values were then compared with those in the non-EA group.
No signiﬁcant diﬀe r e n c e si ni n s u l i no rF F Av a l u e sw e r e
noted between the two groups; however, HOMA values were
signiﬁcantly lower in the EA group than in the non-EA
group (∗∗P<. 05) (Table 1). Changes in HOMA values
were attributed to reductions in insulin and not to FFA
concentrations (Table 1).
3.6. Impact of Atropine on Changes in Insulin, FFA, and
HOMA Values under ICT. Insulin and FFA values in the EA
groupafterICTchallengeandapplicationofEA(15Hz)were
compared with those in the non-EA group under ICT. The
t-test revealed no signiﬁcant diﬀerences in insulin, FFA, or
HOMA values between the two groups (N = 8) (Table 2).
3.7. The Eﬀect of EA on Expression of Insulin Signaling
Proteins. EA (15Hz) was applied to the Zusanli acupoint
i nS T Zr a t su n d e rI C T .T h el e v e l so fI R S - 1a n dA K T - 2
protein expression were then compared between the EA
group and the non-EA group. Western blot analysis revealed
that the levels of IRS-1 and AKT-2 protein expression were
signiﬁcantly higher in rats that received EA than in rats that
did not undergo EA stimulation (Figure 5(a)).
3.8. Atropine Blocks the Eﬀect of EA in Expression of Insulin
Signaling Proteins. After administering Atropine 0.1mg/kg
i.p., EA (15Hz) was applied to the Zusanli acupoint in
S T Zr a t su n d e rI C T .T h el e v e l so fI R S - 1a n dA K T - 2p r o t e i n
expression were then compared between the EA group and
the non-EA group. Western blot analysis revealed that the
levels of IRS-1 and AKT-2 protein expression did not diﬀer
signiﬁcantly between rats that received EA and rats that did
not undergo EA stimulation (Figure 5(b)).6 Experimental Diabetes Research
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Figure 5: (a) The EA-induced change of insulin signals. (b) The blocking eﬀect of atropine on EA-induced change of insulin signals in STZ
rats during ICT. The IRS-1 and AKT-2 ratios to actin were compared between EA and non-EA group by Student’s t-test, ∗P<. 05, ∗∗P<. 01.
4. Discussion
This study shows that EA (15Hz) augmented the glucose-
lowering eﬀects of exogenous insulin in STZ-induced dia-
betic rats (Figure 2). A previous study showed that the blood
glucose-lowering eﬀects of EA are related to the activation
of cholinergic nerves and the adrenal gland in STZ rats
[13]. In this study, Atropine, a cholinergic nerve antagonist,
blocked the glucose-lowering eﬀect of exogenous insulin in
STZ-induced diabetic rats (Figure 3(a)). The results of this
study also show that the blood glucose-lowering eﬀects of
15Hz EA in STZ-diabetic rats that had been subjected to
I C Tc a nb eb l o c k e db yH C - 3( 0 . 0 1m g / k gi . p . )( F i g u r e3(b)).
These results imply that secretion of acetylcholine (Ach) by
cholinergic nerves augments the glucose-lowering eﬀects of
exogenous insulin in STZ rats.
Furthermore, Eserine, a drug that suppresses acetyl
cholinesterase (AchE), causes Ach to accumulate at cholin-
ergic synapses [13, 16, 17]. After a 30 minute exposure to
Eserine (0.01mg/kg i.p.), we found that the levels of plasma
glucose were markedly lower in STZ-induced diabetic rats
that had received EA (15 Hz) stimulation at the Zusanli
acupoints than in rats that did not receive EA stimulation
(P<. 01, Figure 4), indicating that the cholinergic nerves
involve in the increase of the hypoglycemic eﬀect of exoge-
nous insulin by EA.
In order to examine the eﬀect of EA on exogenous
insulin sensitivity, blood insulin and FFA levels were tested.
Since the insulin and FFA levels did not change, and
the HOMA decreased signiﬁcantly after EA in STZ rats
during ICT, we hypothesized that the EA-induced reduction
in glucose was related to reduction in insulin resistance
(Table 1). Furthermore, Atropine blocked the reduction in
theHOMAafterEAtreatment.Theseresultsindicatethatthe
hypoglycemic eﬀectofEAisassociatedwithcholinergictone.
Otherwise, FFA is the important factor in insulin resistance
but it can be ruled out according to the no change by EA
shown in Tables 1 and 2.
A recent study showed that EA oﬀers a beneﬁcial eﬀect
on insulin resistance in obese and diabetic db/db mice, at
least partly, via stimulation of SIRT1/PGC-1α, thus resulting
in improved insulin signaling [20]. Also, in rats with
dihydrotestosterone- (DHT-)induced Polycystic ovary syn-
drome (PCOS), low-frequency EA has been shown to have
systemic and local eﬀects involving intracellular signaling
pathways in muscle that may, at least in part, account for
the marked improvement in insulin sensitivity [21]. In this
study, Western blot was used to examine the expression of
insulin signaling proteins in STZ rats under ICT. The results
showed that IRS-1 and AKT-2 protein expression increased
signiﬁcantly (Figure 5(a)). Also, Atropine was able to block
this message transmission pathway (Figure 5(b)). The results
indicate that the activation of insulin signaling proteins,
at least in part, is related to the cholinergic nerves. This
upregulation of insulin signaling proteins was also obtained
in a STZ-induced diabetic rat [13] and in a steroid-induced
insulin resistance rat model [10]. This is the ﬁrst time to
report that the upregulation of insulin signaling proteins
(IRS-1 and AKT-2) was obtained in a STZ-induced diabetic
rat under ICT by EA. The phosphorylation of these signal
proteins and further inﬂuence of insulin signal pathway
deserve further research.
These results suggest that EA augments the blood
glucose-lowering eﬀect of EA in STZ rats that have been
subjected to insulin challenge through the activation of the
cholinergic nerves. This may be related to enhancement of
insulin signaling rather than to change in insulin and FFA
concentration.Experimental Diabetes Research 7
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